Symbols / KOD Stock $45.21 +0.04% Kodiak Sciences Inc.
KOD (Stock) Chart
About
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Stock Fundamentals
Scroll to Statements| Market Cap | 2.81B | Enterprise Value | 2.64B | Income | -229.97M | Sales | — | Book/sh | 2.55 | Cash/sh | 3.40 |
| Dividend Yield | — | Payout | 0.00% | Employees | 124 | IPO | — | P/E | — | Forward P/E | -13.23 |
| PEG | — | P/S | — | P/B | 17.71 | P/C | — | EV/EBITDA | -12.22 | EV/Sales | — |
| Quick Ratio | 4.61 | Current Ratio | 4.72 | Debt/Eq | 37.60 | LT Debt/Eq | — | EPS (ttm) | -4.32 | EPS next Y | -3.42 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-13 | ROA | -42.64% | ROE | -149.49% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 62.16M | Shs Float | 39.09M | Short Float | 23.68% |
| Short Ratio | 6.26 | Short Interest | — | 52W High | 47.84 | 52W Low | 2.81 | Beta | 2.40 | Avg Volume | 1.09M |
| Volume | 634.01K | Target Price | $56.33 | Recom | None | Prev Close | $45.19 | Price | $45.21 | Change | 0.04% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-27 | main | UBS | Buy → Buy | $80 |
| 2026-03-27 | reit | HC Wainwright & Co. | Buy → Buy | $58 |
| 2026-02-10 | reit | HC Wainwright & Co. | Buy → Buy | $38 |
| 2026-01-22 | main | HC Wainwright & Co. | Buy → Buy | $38 |
| 2026-01-07 | init | UBS | — → Buy | $50 |
| 2025-11-17 | main | Chardan Capital | Neutral → Neutral | $14 |
| 2025-11-17 | main | HC Wainwright & Co. | Buy → Buy | $26 |
| 2025-11-11 | up | HC Wainwright & Co. | Neutral → Buy | $24 |
| 2025-10-24 | up | JP Morgan | Neutral → Overweight | $24 |
| 2025-10-23 | init | LifeSci Capital | — → Outperform | $40 |
| 2025-10-06 | main | Chardan Capital | Neutral → Neutral | $14 |
| 2025-09-25 | up | Barclays | Underweight → Equal-Weight | $17 |
| 2025-09-22 | init | Jefferies | — → Buy | $15 |
| 2025-08-18 | main | HC Wainwright & Co. | Neutral → Neutral | $5 |
| 2025-08-14 | main | Barclays | Underweight → Underweight | $7 |
| 2025-08-14 | up | JP Morgan | Underweight → Neutral | $15 |
| 2025-03-31 | reit | HC Wainwright & Co. | Neutral → Neutral | $3 |
| 2024-12-09 | up | Jefferies | Hold → Buy | $20 |
| 2024-11-15 | main | Barclays | Underweight → Underweight | $4 |
| 2024-11-15 | reit | HC Wainwright & Co. | Neutral → Neutral | $3 |
News
RSS: Latest KOD news- Why did KOD stock surge 40% in pre-market today? - MSN hu, 23 Apr 2026 17
- Kodiak Sciences: Road To $120 - Forbes Mon, 30 Mar 2026 07
- Is Kodiak Sciences (KOD) stock stronger than industry leaders (-1.28%) 2026-04-22 - Diversification - Cổng thông tin điện tử tỉnh Lào Cai Wed, 22 Apr 2026 15
- Kodiak Sciences Inc (KOD): What’s the Chance of Success for Zenkuda? - Insider Monkey hu, 23 Apr 2026 09
- KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate - Yahoo Finance Fri, 27 Mar 2026 07
- How Kodiak Sciences Stock Rises To $120? - Trefis Fri, 27 Mar 2026 07
- KOD SEC Filings - Kodiak Sciences Inc. 10-K, 10-Q, 8-K Forms - Stock Titan Sat, 11 Apr 2026 03
- Kodiak Sciences KOD Stock Soars On Phase 3 Win - timothysykes.com Fri, 17 Apr 2026 21
- KOD Kodiak Sciences Inc reports narrow Q4 2025 EPS beat, shares drop 3.74 percent on weak investor sentiment. - Viral Trade Signals - Cổng thông tin điện tử tỉnh Tây Ninh Wed, 22 Apr 2026 18
- Assessing Kodiak Sciences (KOD) Valuation After Recent Share Price Momentum And Conflicting Signals - Yahoo Finance Mon, 06 Apr 2026 07
- Kodiak Sciences (NASDAQ: KOD) CFO exercises options, now holds 211,930 shares - Stock Titan hu, 16 Apr 2026 21
- KOD Stock Up 24% in 3 Months: Here's What You Need to Know - Yahoo Finance Fri, 06 Feb 2026 08
- Kodiak says eye drug is BLA-ready after Phase 3 diabetic retinopathy win - Stock Titan ue, 31 Mar 2026 07
- 10 Best 52-Week High US Stocks to Buy - Insider Monkey hu, 23 Apr 2026 04
- Kodiak Sciences (KOD) Stock: Downtrend Signals? (Loses Ground) 2026-04-15 - Post Earnings - Xã Vĩnh Công Wed, 15 Apr 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
234.39
+25.44%
|
186.85
-32.62%
|
277.32
-18.76%
|
341.38
|
| Research And Development |
|
182.37
+44.63%
|
126.09
-38.88%
|
206.30
-22.91%
|
267.59
|
| Selling General And Administration |
|
52.02
-14.38%
|
60.75
-14.46%
|
71.02
-3.75%
|
73.79
|
| General And Administrative Expense |
|
52.02
-14.38%
|
60.75
-14.46%
|
71.02
-3.75%
|
73.79
|
| Other Gand A |
|
52.02
-14.38%
|
60.75
-14.46%
|
71.02
-3.75%
|
73.79
|
| Total Expenses |
|
234.39
+25.44%
|
186.85
-32.62%
|
277.32
-18.76%
|
341.38
|
| Operating Income |
|
-234.39
-25.44%
|
-186.85
+32.62%
|
-277.32
+18.76%
|
-341.38
|
| Total Operating Income As Reported |
|
-234.39
-25.44%
|
-186.85
+32.62%
|
-277.32
+18.76%
|
-341.38
|
| EBITDA |
|
-203.65
-36.22%
|
-149.50
+36.26%
|
-234.53
+27.35%
|
-322.80
|
| Normalized EBITDA |
|
-203.65
-36.22%
|
-149.50
+36.26%
|
-234.53
+27.35%
|
-322.80
|
| Reconciled Depreciation |
|
26.32
-1.45%
|
26.71
+2.93%
|
25.95
+135.86%
|
11.00
|
| EBIT |
|
-229.97
-30.51%
|
-176.21
+32.35%
|
-260.48
+21.97%
|
-333.81
|
| Net Income |
|
-229.97
-30.51%
|
-176.21
+32.36%
|
-260.49
+21.97%
|
-333.82
|
| Pretax Income |
|
-229.97
-30.51%
|
-176.21
+32.36%
|
-260.49
+21.97%
|
-333.82
|
| Net Non Operating Interest Income Expense |
|
4.52
-59.48%
|
11.15
-33.33%
|
16.72
+137.06%
|
7.05
|
| Interest Expense Non Operating |
|
0.00
|
0.00
-100.00%
|
0.01
-27.78%
|
0.02
|
| Net Interest Income |
|
4.52
-59.48%
|
11.15
-33.33%
|
16.72
+137.06%
|
7.05
|
| Interest Expense |
|
0.00
|
0.00
-100.00%
|
0.01
-27.78%
|
0.02
|
| Interest Income Non Operating |
|
4.52
-59.48%
|
11.15
-33.38%
|
16.73
+136.64%
|
7.07
|
| Interest Income |
|
4.52
-59.48%
|
11.15
-33.38%
|
16.73
+136.64%
|
7.07
|
| Other Income Expense |
|
-0.10
+81.03%
|
-0.51
-560.00%
|
0.11
-78.13%
|
0.50
|
| Other Non Operating Income Expenses |
|
-0.10
+81.03%
|
-0.51
-560.00%
|
0.11
-78.13%
|
0.50
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-229.97
-30.51%
|
-176.21
+32.36%
|
-260.49
+21.97%
|
-333.82
|
| Net Income From Continuing Operation Net Minority Interest |
|
-229.97
-30.51%
|
-176.21
+32.36%
|
-260.49
+21.97%
|
-333.82
|
| Net Income From Continuing And Discontinued Operation |
|
-229.97
-30.51%
|
-176.21
+32.36%
|
-260.49
+21.97%
|
-333.82
|
| Net Income Continuous Operations |
|
-229.97
-30.51%
|
-176.21
+32.36%
|
-260.49
+21.97%
|
-333.82
|
| Normalized Income |
|
-229.97
-30.51%
|
-176.21
+32.36%
|
-260.49
+21.97%
|
-333.82
|
| Net Income Common Stockholders |
|
-229.97
-30.51%
|
-176.21
+32.36%
|
-260.49
+21.97%
|
-333.82
|
| Diluted EPS |
|
-4.32
-28.96%
|
-3.35
+32.60%
|
-4.97
+22.22%
|
-6.39
|
| Basic EPS |
|
-4.32
-28.96%
|
-3.35
+32.60%
|
-4.97
+22.22%
|
-6.39
|
| Basic Average Shares |
|
53.21
+1.19%
|
52.58
+0.32%
|
52.41
+0.32%
|
52.25
|
| Diluted Average Shares |
|
53.21
+1.19%
|
52.58
+0.32%
|
52.41
+0.32%
|
52.25
|
| Diluted NI Availto Com Stockholders |
|
-229.97
-30.51%
|
-176.21
+32.36%
|
-260.49
+21.97%
|
-333.82
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
351.53
+4.75%
|
335.58
-30.00%
|
479.37
-28.09%
|
666.63
|
| Current Assets |
|
214.82
+24.94%
|
171.94
-40.57%
|
289.31
-40.47%
|
486.00
|
| Cash Cash Equivalents And Short Term Investments |
|
209.86
+24.86%
|
168.07
-41.13%
|
285.51
-40.39%
|
478.93
|
| Cash And Cash Equivalents |
|
209.86
+24.86%
|
168.07
-41.13%
|
285.51
+49.93%
|
190.43
|
| Cash Equivalents |
|
207.59
+24.70%
|
166.46
|
—
|
—
|
| Cash Financial |
|
2.28
+41.43%
|
1.61
|
—
|
—
|
| Other Short Term Investments |
|
—
|
—
|
0.00
-100.00%
|
288.50
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
4.95
+28.28%
|
3.86
+1.58%
|
3.80
-46.24%
|
7.07
|
| Total Non Current Assets |
|
136.72
-16.45%
|
163.64
-13.90%
|
190.06
+5.23%
|
180.62
|
| Net PPE |
|
121.86
-18.06%
|
148.73
-15.02%
|
175.02
+51.20%
|
115.75
|
| Gross PPE |
|
181.34
-4.56%
|
189.99
-3.84%
|
197.57
+61.32%
|
122.48
|
| Accumulated Depreciation |
|
-59.47
-44.13%
|
-41.26
-82.96%
|
-22.55
-235.40%
|
-6.72
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
43.06
+0.73%
|
42.75
+1.46%
|
42.13
+178.89%
|
15.11
|
| Construction In Progress |
|
5.16
+22.67%
|
4.20
-3.82%
|
4.37
-3.28%
|
4.52
|
| Other Properties |
|
36.61
-21.29%
|
46.51
-14.73%
|
54.54
-8.13%
|
59.37
|
| Leases |
|
96.51
-0.02%
|
96.53
+0.00%
|
96.53
+122.00%
|
43.48
|
| Other Non Current Assets |
|
14.85
-0.40%
|
14.91
-0.85%
|
15.04
-76.82%
|
64.87
|
| Total Liabilities Net Minority Interest |
|
194.15
+4.78%
|
185.29
-13.25%
|
213.59
-7.32%
|
230.46
|
| Current Liabilities |
|
45.53
+78.05%
|
25.57
-38.72%
|
41.73
-20.51%
|
52.50
|
| Payables And Accrued Expenses |
|
33.47
+123.95%
|
14.95
-53.24%
|
31.96
-24.93%
|
42.57
|
| Payables |
|
12.86
+228.56%
|
3.92
-71.23%
|
13.61
+49.05%
|
9.13
|
| Accounts Payable |
|
12.86
+228.56%
|
3.92
-71.23%
|
13.61
+49.05%
|
9.13
|
| Current Accrued Expenses |
|
20.61
+86.83%
|
11.03
-39.89%
|
18.35
-45.12%
|
33.44
|
| Current Debt And Capital Lease Obligation |
|
12.06
+13.50%
|
10.63
+8.78%
|
9.77
-1.57%
|
9.93
|
| Current Capital Lease Obligation |
|
12.06
+13.50%
|
10.63
+8.78%
|
9.77
-1.57%
|
9.93
|
| Other Current Liabilities |
|
—
|
—
|
—
|
-0.00
|
| Total Non Current Liabilities Net Minority Interest |
|
148.62
-6.95%
|
159.72
-7.07%
|
171.86
-3.43%
|
177.97
|
| Long Term Debt And Capital Lease Obligation |
|
47.12
-21.10%
|
59.72
-16.90%
|
71.86
-7.64%
|
77.81
|
| Long Term Capital Lease Obligation |
|
47.12
-21.10%
|
59.72
-16.90%
|
71.86
-7.64%
|
77.81
|
| Tradeand Other Payables Non Current |
|
—
|
—
|
—
|
0.00
|
| Other Non Current Liabilities |
|
101.50
+1.50%
|
100.00
+0.00%
|
100.00
-0.16%
|
100.16
|
| Stockholders Equity |
|
157.38
+4.72%
|
150.29
-43.45%
|
265.78
-39.06%
|
436.17
|
| Common Stock Equity |
|
157.38
+4.72%
|
150.29
-43.45%
|
265.78
-39.06%
|
436.17
|
| Capital Stock |
|
0.01
+20.00%
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
|
| Common Stock |
|
0.01
+20.00%
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
61.76
+17.13%
|
52.73
+0.42%
|
52.51
+0.33%
|
52.33
|
| Ordinary Shares Number |
|
61.76
+17.13%
|
52.73
+0.42%
|
52.51
+0.33%
|
52.33
|
| Additional Paid In Capital |
|
1,716.08
+16.03%
|
1,479.02
+4.28%
|
1,418.31
+6.68%
|
1,329.51
|
| Retained Earnings |
|
-1,558.70
-17.31%
|
-1,328.74
-15.29%
|
-1,152.53
-29.20%
|
-892.04
|
| Gains Losses Not Affecting Retained Earnings |
|
—
|
—
|
0.00
+100.00%
|
-1.31
|
| Other Equity Adjustments |
|
—
|
—
|
—
|
-1.31
|
| Total Equity Gross Minority Interest |
|
157.38
+4.72%
|
150.29
-43.45%
|
265.78
-39.06%
|
436.17
|
| Total Capitalization |
|
157.38
+4.72%
|
150.29
-43.45%
|
265.78
-39.06%
|
436.17
|
| Working Capital |
|
169.28
+15.66%
|
146.36
-40.88%
|
247.58
-42.89%
|
433.51
|
| Invested Capital |
|
157.38
+4.72%
|
150.29
-43.45%
|
265.78
-39.06%
|
436.17
|
| Total Debt |
|
59.18
-15.87%
|
70.34
-13.83%
|
81.63
-6.95%
|
87.73
|
| Capital Lease Obligations |
|
59.18
-15.87%
|
70.34
-13.83%
|
81.63
-6.95%
|
87.73
|
| Net Tangible Assets |
|
157.38
+4.72%
|
150.29
-43.45%
|
265.78
-39.06%
|
436.17
|
| Tangible Book Value |
|
157.38
+4.72%
|
150.29
-43.45%
|
265.78
-39.06%
|
436.17
|
| Dueto Related Parties Non Current |
|
—
|
—
|
—
|
100.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-136.01
-15.93%
|
-117.32
+23.91%
|
-154.18
+25.32%
|
-206.46
|
| Cash Flow From Continuing Operating Activities |
|
-136.01
-15.93%
|
-117.32
+23.91%
|
-154.18
+25.32%
|
-206.46
|
| Net Income From Continuing Operations |
|
-229.97
-30.51%
|
-176.21
+32.36%
|
-260.49
+21.97%
|
-333.82
|
| Depreciation Amortization Depletion |
|
26.32
-1.45%
|
26.71
+2.93%
|
25.95
+135.86%
|
11.00
|
| Depreciation |
|
26.32
-1.45%
|
26.71
+2.93%
|
25.95
+135.86%
|
11.00
|
| Depreciation And Amortization |
|
26.32
-1.45%
|
26.71
+2.93%
|
25.95
+135.86%
|
11.00
|
| Other Non Cash Items |
|
0.02
-94.37%
|
0.35
+142.26%
|
-0.84
-49.20%
|
-0.56
|
| Stock Based Compensation |
|
58.86
-2.24%
|
60.21
-32.01%
|
88.56
-16.48%
|
106.03
|
| Asset Impairment Charge |
|
1.91
|
0.00
|
0.00
|
—
|
| Operating Gains Losses |
|
—
|
—
|
0.00
|
—
|
| Gain Loss On Sale Of PPE |
|
—
|
0.00
-100.00%
|
0.00
|
0.00
|
| Change In Working Capital |
|
6.85
+124.12%
|
-28.39
-285.94%
|
-7.36
-161.49%
|
11.96
|
| Change In Prepaid Assets |
|
0.61
+1115.00%
|
-0.06
-100.71%
|
8.45
+407.98%
|
-2.74
|
| Change In Payables And Accrued Expense |
|
17.34
+201.64%
|
-17.06
-133.43%
|
-7.31
-1147.44%
|
-0.59
|
| Change In Accrued Expense |
|
9.27
+225.80%
|
-7.37
+42.89%
|
-12.91
-474.67%
|
-2.25
|
| Change In Payable |
|
8.07
+183.26%
|
-9.69
-273.18%
|
5.60
+237.17%
|
1.66
|
| Change In Account Payable |
|
8.07
+183.26%
|
-9.69
-273.18%
|
5.60
+237.17%
|
1.66
|
| Change In Other Current Assets |
|
0.06
+591.67%
|
-0.01
-102.82%
|
0.43
-94.23%
|
7.38
|
| Change In Other Current Liabilities |
|
-11.16
+0.76%
|
-11.25
-26.09%
|
-8.92
-212.84%
|
7.91
|
| Investing Cash Flow |
|
-0.51
+32.98%
|
-0.76
-100.30%
|
249.23
+174.06%
|
-336.51
|
| Cash Flow From Continuing Investing Activities |
|
-0.51
+32.98%
|
-0.76
-100.30%
|
249.23
+174.06%
|
-336.51
|
| Net PPE Purchase And Sale |
|
-0.51
-26.50%
|
-0.40
+99.03%
|
-41.43
+12.53%
|
-47.36
|
| Purchase Of PPE |
|
-0.51
-26.50%
|
-0.40
+99.03%
|
-41.43
+12.53%
|
-47.36
|
| Capital Expenditure |
|
-0.51
-26.50%
|
-0.40
+99.03%
|
-41.43
+12.53%
|
-47.36
|
| Net Investment Purchase And Sale |
|
0.00
+100.00%
|
-0.35
-100.12%
|
290.65
+200.52%
|
-289.15
|
| Purchase Of Investment |
|
0.00
+100.00%
|
-0.35
+99.28%
|
-49.35
+88.46%
|
-427.77
|
| Sale Of Investment |
|
0.00
|
0.00
-100.00%
|
340.00
+145.28%
|
138.62
|
| Financing Cash Flow |
|
178.30
+35489.22%
|
0.50
+1516.13%
|
0.03
-98.36%
|
1.90
|
| Cash Flow From Continuing Financing Activities |
|
178.30
+35489.22%
|
0.50
+1516.13%
|
0.03
-98.36%
|
1.90
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
0.00
|
| Repayment Of Debt |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Net Common Stock Issuance |
|
172.96
|
0.00
|
0.00
|
0.00
|
| Common Stock Payments |
|
—
|
—
|
—
|
0.00
|
| Repurchase Of Capital Stock |
|
—
|
—
|
—
|
0.00
|
| Proceeds From Stock Option Exercised |
|
5.34
+966.27%
|
0.50
+107.02%
|
0.24
-87.55%
|
1.94
|
| Net Other Financing Charges |
|
—
|
—
|
-0.21
-330.61%
|
-0.05
|
| Changes In Cash |
|
41.79
+135.54%
|
-117.57
-223.66%
|
95.07
+117.57%
|
-541.08
|
| Beginning Cash Position |
|
174.26
-40.29%
|
291.83
+48.32%
|
196.76
-73.33%
|
737.83
|
| End Cash Position |
|
216.05
+23.98%
|
174.26
-40.29%
|
291.83
+48.32%
|
196.76
|
| Free Cash Flow |
|
-136.51
-15.97%
|
-117.72
+39.82%
|
-195.61
+22.93%
|
-253.82
|
| Interest Paid Supplemental Data |
|
0.00
|
0.00
-100.00%
|
0.01
-27.78%
|
0.02
|
| Amortization Of Securities |
|
—
|
0.00
+100.00%
|
-0.85
+20.79%
|
-1.07
|
| Common Stock Issuance |
|
172.96
|
0.00
|
0.00
|
0.00
|
| Issuance Of Capital Stock |
|
172.96
|
0.00
|
0.00
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-16 View
- 42026-04-02 View
- 10-K2026-03-31 View
- 8-K2026-03-31 View
- 42026-03-27 View
- 8-K2026-03-27 View
- 42026-03-19 View
- 42025-12-19 View
- 8-K2025-12-18 View
- 10-Q2025-11-13 View
- 8-K2025-11-13 View
- 10-Q2025-08-13 View
- 8-K2025-08-13 View
- 42025-07-08 View
- 42025-07-08 View
- 42025-07-02 View
- 42025-07-02 View
- 42025-07-02 View
- 42025-07-02 View
- 42025-07-02 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|